Finding 366946 (2023-002)

Significant Deficiency Repeat Finding
Requirement
L
Questioned Costs
-
Year
2023
Accepted
2024-02-13

AI Summary

  • Core Issue: Lack of proper supervisory review and approval in grant reporting processes.
  • Impacted Requirements: Internal control standards require timely and documented supervisory reviews for compliance.
  • Recommended Follow-Up: Ensure the Treasurer reviews and documents approval of all grant reports before submission.

Finding Text

2023-002 – CONTROLS OVER GRANT REPORTING (93.788 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES) Condition: The Association does not have appropriate supervisory review and approval procedures in the grant reporting function within the internal control framework. Criteria: Effective internal control over compliance includes appropriate, timely, and documented supervisory review and approval procedures. Cause: The grant reporting is prepared and submitted by the program manager without documented supervisory review and approval. Effect: The Association is at an increased risk for grant reporting errors or omissions without timely supervisory review and approval. Questioned Costs: N/A Recommendation: We recommend the Treasurer review and approve all future grant reports prior to their submission. The approval should be documented in writing. Views of Responsible Officials: Management concurs with the finding and has developed a plan to correct the finding.

Corrective Action Plan

CONTROLS OVER GRANT REPORTING Department of Health and Human Services 93.788 Management within West Virginia Public Transit Association appreciates and shares the auditors’ concern with integrity as it relates to controls over grant reporting. The State Opioid Response Transportation Project Manager will submit all future grant reports to the West Virginia Public Transit Association Treasurer for review prior to submission to grantor. The Treasurer will document approval in writing. This will begin with the quarter ending September 29, 2023.

Categories

Reporting Internal Control / Segregation of Duties

Other Findings in this Audit

  • 366945 2023-001
    - Repeat
  • 366947 2023-001
    - Repeat
  • 366948 2023-002
    Significant Deficiency Repeat
  • 943387 2023-001
    - Repeat
  • 943388 2023-002
    Significant Deficiency Repeat
  • 943389 2023-001
    - Repeat
  • 943390 2023-002
    Significant Deficiency Repeat

Programs in Audit

ALN Program Name Expenditures
93.788 Opioid Str $1.82M